Analyst Ratings For NASDAQ:BMRN – BioMarin Pharmaceutical (NASDAQ:BMRN)
Today, Canaccord Genuity raised its price target on NASDAQ:BMRN – BioMarin Pharmaceutical (NASDAQ:BMRN) to per share.
Some recent analyst ratings include
- 5/15/2018-Wedbush Reiterated Rating of Outperform.
- 3/29/2018-Credit Suisse Group Reiterated Rating of Buy.
- On 5/17/2018 Jean Jacques Bienaime, CEO, sold 18,750 with an average share price of $88.66 per share and the total transaction amounting to $1,662,375.00.
- On 5/15/2018 Jean Jacques Bienaime, CEO, sold 37,500 with an average share price of $88.75 per share and the total transaction amounting to $3,328,125.00.
- On 5/11/2018 Jean Jacques Bienaime, CEO, sold 18,750 with an average share price of $88.42 per share and the total transaction amounting to $1,657,875.00.
- On 5/10/2018 Brian Mueller, SVP, sold 2,450 with an average share price of $89.50 per share and the total transaction amounting to $219,275.00.
- On 5/7/2018 Jeffrey Robert Ajer, EVP, sold 309 with an average share price of $85.96 per share and the total transaction amounting to $26,561.64.
- On 4/24/2018 Jean Jacques Bienaime, CEO, sold 20,000 with an average share price of $82.43 per share and the total transaction amounting to $1,648,600.00.
- On 4/23/2018 Daniel K Spiegelman, CFO, sold 11,059 with an average share price of $82.15 per share and the total transaction amounting to $908,496.85.
Recent Trading Activity for NASDAQ:BMRN – BioMarin Pharmaceutical (NASDAQ:BMRN)
Shares of NASDAQ:BMRN – BioMarin Pharmaceutical closed the previous trading session at 91.17 up +2.89 3.27% with 90.29399871826172 shares trading hands.